CorMedix (CRMD) announced that DefenCath has received an Innovative Technology designation from Vizient.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix price target raised to $22 from $21 at RBC Capital
- Cormedix’s Strong Financial Performance and Promising Prospects Drive Buy Rating
- Midday Fly By: AWS hit by outage, Kering sells beauty unit
- Morning Movers: Cleveland-Cliffs surges following earnings report
- CorMedix upgraded to Buy from Hold at D. Boral Capital